These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36201738)

  • 1. Is PHARMAC's decision-making fair, cost-effective and clinically effective? Observations from the real world.
    Bolland MJ; Grey A
    N Z Med J; 2022 Oct; 135(1563):114-118. PubMed ID: 36201738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is PHARMAC's decision making fair? Findings from an evaluation of decision-making in the New Zealand health system.
    Tumilty E; Doolan-Noble F; Gauld R; Littlejohns P; Stokes T
    N Z Med J; 2022 Feb; 135(1550):170-177. PubMed ID: 35728164
    [No Abstract]   [Full Text] [Related]  

  • 3. Reimbursement of pharmaceuticals in New Zealand: comments on PHARMAC's processes.
    Swinburn B; Milne RJ; Richards M; Begg E; Foote S; Jackson R
    N Z Med J; 2000 Oct; 113(1119):425-8. PubMed ID: 11127362
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis.
    Grocott R; Metcalfe S; Alexander P; Werner R
    N Z Med J; 2013 Jul; 126(1378):60-73. PubMed ID: 24045316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rate.
    Grocott R; Metcalfe S
    N Z Med J; 2007 Jul; 120(1258):U2641. PubMed ID: 17653257
    [No Abstract]   [Full Text] [Related]  

  • 6. PHARMAC's response on clopidogrel.
    Moodie P; Dougherty S
    N Z Med J; 2006 Feb; 119(1229):U1872. PubMed ID: 16498486
    [No Abstract]   [Full Text] [Related]  

  • 7. PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric.
    Grocott R; Metcalfe S
    N Z Med J; 2012 Jul; 125(1358):89-90. PubMed ID: 22864151
    [No Abstract]   [Full Text] [Related]  

  • 8. The influence of PHARMAC's National Hospital Pharmaceutical Strategy on Quality Use of Medicines activities in New Zealand hospitals.
    Tordoff J; Norris P; Kennedy J; Reith D
    N Z Med J; 2006 Aug; 119(1239):U2100. PubMed ID: 16912718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision.
    Isaacs RJ; Frampton CM; Kuper-Hommel MJ
    N Z Med J; 2007 Aug; 120(1259):U2676. PubMed ID: 17721579
    [No Abstract]   [Full Text] [Related]  

  • 10. PHARMAC's effectiveness threatened by TPPA restrictions.
    Nurs N Z; 2012 Oct; 18(9):7. PubMed ID: 23311095
    [No Abstract]   [Full Text] [Related]  

  • 11. Regarding 'Is PHARMAC's sole-supply tendering policy harming the health of New Zealanders?' editorial.
    Gray B
    N Z Med J; 2005 May; 118(1215):U1481; discussion U1481. PubMed ID: 15915196
    [No Abstract]   [Full Text] [Related]  

  • 12. Merck responds to PHARMAC's article on COX-2 inhibitors.
    Woolner D
    N Z Med J; 2005 Nov; 118(1225):U1746. PubMed ID: 16286953
    [No Abstract]   [Full Text] [Related]  

  • 13. [Interpretation of modified prescription for pharmacoeconomic analysis of New Zealand].
    Wang X; Su X; Gao Y; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2840-3. PubMed ID: 22292380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PHARMAC's response on gemcitabine and transparency.
    Crausaz S; Metcalfe S
    N Z Med J; 2005 Nov; 118(1225):U1741. PubMed ID: 16286949
    [No Abstract]   [Full Text] [Related]  

  • 15. PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly.
    Metcalfe S; Crausaz S; Moodie P; McNee W
    N Z Med J; 2005 Dec; 118(1227):U1806. PubMed ID: 16372042
    [No Abstract]   [Full Text] [Related]  

  • 16. Is PHARMAC's sole-supply tendering policy harming the health of New Zealanders?
    MacKay P
    N Z Med J; 2005 May; 118(1214):U1433. PubMed ID: 15886729
    [No Abstract]   [Full Text] [Related]  

  • 17. PHARMAC and lack of funding for clopidogrel.
    White H; Ellis C
    N Z Med J; 2005 Jan; 119(1228):U1808. PubMed ID: 16462916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypnosedative access and risk of harm.
    Menkes DB; Shieffelbien LM; Huthwaite M
    N Z Med J; 2011 Nov; 124(1345):69-73. PubMed ID: 22072169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary.
    Gauld R
    Pharmacoeconomics; 2014 Oct; 32(10):937-42. PubMed ID: 24906479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
    Rosevear M
    N Z Med J; 2006 Jun; 119(1235):U2014. PubMed ID: 16751832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.